Long-term effects of ranibizumab on diabetic retinopathy severity and progression

Archives of Ophthalmology

Volumn 130, Issue 9, 2012, Pages 1145-1152

  Ip, Michael S ^a   Domalpally, Amitha ^a   Hopkins, J Jill ^b   Wong, Pamela ^b   Ehrlich, Jason S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; RETINA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VISUAL ACUITY;

EID: 84866117381     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2012.1043     Document Type: Article

References (24)

1. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines: diabetic retinopathy PPP. San Francisco, CA: American Academy of Ophthalmology; 2008. http://one.aao.org/CE/PracticeGuidelines/PPP. aspx.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology. 1984;91(12):1464-1474. (Pubitemid 15197017)
4. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5)(suppl):786-806.
5. Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001;119(4):547-553. (Pubitemid 32290063)
6. National Center for Chronic Disease Prevention and Health Promotion Division of Diabetes Translation. National diabetes fact sheet, 2011: national estimates and general information on diabetes and prediabetes in the United States. http: //www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed December 23, 2011.
7. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report No. 14. Int Ophthalmol Clin. 1987;27(4):239-253.
8. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991; 98(5)(suppl):766-785.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med . 1993; 329(14):977-986.
11. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51.
12. Sjølie AK, Klein R, Porta M, et al; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372 (9647):1385-1393.
13. Bressler NM, Edwards AR, Beck RW, et al Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009;127(12):1566-1571.
14. ElmanMJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064-1077, e35.
15. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8):1580-1587.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. (Pubitemid 24356306)
17. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci . 2001;42(10):2408-2413. (Pubitemid 32848873)
18. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103(11):1820-1828. (Pubitemid 26403735)
19. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445-450. (Pubitemid 24307211)
20. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull . 2008;31(8):1541-1546.
21. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008; 57(4):1026-1033.
22. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials [published online February 11, 2011]. Ophthalmology. http://dx.doi.org/10.1016/j.ophtha.2011.12.039.
23. Adamis AP, Altaweel M, Bressler NM, et al Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23-28. (Pubitemid 43021723)
24. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.